Literature DB >> 2452181

Measurement of catecholamines, met-enkephalin, somatostatin and substance P-like immunoreactivities in 12 human pheochromocytomas.

E Baldi1, M L De Feo, P Geppetti, V Carlà, M Maggi, C Pupilli, M G Spillantini, A Brocchi, M Mannelli.   

Abstract

The present study was designed to evaluate the simultaneous presence of epinephrine (E), norepinephrine (NE), met-enkephalin (ME)-, somatostatin (SRIF)- and substance P (SP)- like immunoreactivities (LI) in extracts of 12 pheochromocytomas obtained at the time of surgery from 10 patients. Moreover, catecholamines and ME-LI levels were measured in peripheral plasma of each patient. Each pheochromocytoma was characterized by a high variability of ME-LI, SRIF-LI, SP-LI, E and NE levels. The highest E concentrations were found in tumors from patients with Multiple Endocrine Adenomatosis (MEA) IIa syndrome, whereas in sporadic pheochromocytomas NE was the main catecholamine. Among the neuropeptides ME-LI showed the highest intratumoral concentration, and SP-LI the lowest. No correlations were found between intratumoral levels of catecholamines and any of the neuropeptides or between any of the different neuropeptides measured. Plasma catecholamine levels were not correlated with intratumoral catecholamine levels. Plasma ME-LI was higher than normal in only one patient. No correlation was observed between tumoral CA or peptide content and the clinical picture. Our study confirms that human pheochromocytoma cells can synthetize different neuropeptides. The variability of the clinical picture very likely depends on the biochemical and biological heterogeneity of this chromaffin tumor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452181     DOI: 10.1007/BF03350121

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Naloxone administration releases catecholamines.

Authors:  M Mannelli; M Maggi; M L De Feo; S Cuomo; G Forti; F Moroni; G Giusti
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

2.  Enkephalin in peripheral neuroendocrine tumours.

Authors:  S N Sullivan; S R Bloom; J M Polak
Journal:  Lancet       Date:  1978-05-06       Impact factor: 79.321

3.  [A case of VIP and somatostatin-secreting phaeochromocytoma (author's transl)].

Authors:  J P Faurel; P Bernard; T Saigot; O Bousquet; A Sarrazin
Journal:  Nouv Presse Med       Date:  1982-04-24

4.  Simultaneous evaluation of the catecholamine pathway and three opioid peptide-producing systems in human pheochromocytomas.

Authors:  F Cesselin; L Pique; X Bertagna; C Benlot; J Antréassian; M F Proeschel; F Girard; F Zogbi; J C Legrand; J P Luton
Journal:  Neuropeptides       Date:  1984-03       Impact factor: 3.286

5.  Plasma methionine-enkephalin and leucine-enkephalin in normal subjects and patients with pheochromocytoma.

Authors:  T Yoshimasa; K Nakao; S Li; Y Ikeda; M Suda; M Sakamoto; H Imura
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

6.  Neuropeptide tyrosine (NPY) immunoreactivity in norepinephrine-containing cells and nerves of the mammalian adrenal gland.

Authors:  I M Varndell; J M Polak; J M Allen; G Terenghi; S R Bloom
Journal:  Endocrinology       Date:  1984-04       Impact factor: 4.736

7.  Enkephalin- and somatostatin-like immunoreactivities in human adrenal medulla and pheochromocytoma.

Authors:  J M Lundberg; B Hamberger; M Schultzberg; T Hökfelt; P O Granberg; S Efendić; L Terenius; M Goldstein; R Luft
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

8.  Vasoactive intestinal polypeptide-, somatostatin-, and calcitonin-producing adrenal pheochromocytoma associated with the watery diarrhea (WDHH) syndrome. First case report with immunohistochemical findings.

Authors:  G Viale; P Dell'Orto; E Moro; L Cozzaglio; G Coggi
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

9.  Pharmacological characterization of adrenal paraneurons: substance P and somatostatin as inhibitory modulators of the nicotinic response.

Authors:  F Mizobe; V Kozousek; D M Dean; B G Livett
Journal:  Brain Res       Date:  1979-12-14       Impact factor: 3.252

10.  Demonstration and characterization of immunoreactive methionine-enkephalin, leucine-enkephalin, methionine-enkephalin-Arg6-Gly7-Leu8 and methionine-enkephalin-Arg6-Phe7 in human phaeochromocytoma.

Authors:  T Yoshimasa; K Nakao; M Sakamoto; M Suda; N Morii; Y Ikeda; T Ishihara; M Manno; S Hamada; S Shimbo
Journal:  Acta Endocrinol (Copenh)       Date:  1984-10
View more
  3 in total

1.  Augmented enkephalin-immunoreactivity in adrenaline-producing phaeochromocytomas.

Authors:  T Kodama; C Ito; Y Fujimoto; Y Ito; T Obara; A Hirayama
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 2.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

Review 3.  Subclinical phaeochromocytoma.

Authors:  Massimo Mannelli; Jacques W M Lenders; Karel Pacak; Gabriele Parenti; Graeme Eisenhofer
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.